Wnt/β-catenin Signaling Pathway: an Attractive Potential Therapeutic Target in Osteosarcoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2025 Mar 3

PMID 40028002

Authors

Yi Ding

Qin Chen

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) is the most common bone malignancy in children and adolescents, and although current neoadjuvant chemotherapy has shown efficacy against OS, the long-term survival rate for patients with OS remains low, highlighting the need to find more effective treatments. In cancer cells, abnormal activation of signaling pathways can widely affect cell activity from growth and proliferation to apoptosis, invasion and metastasis. Wnt/β-catenin is a complex and unique signaling pathway that is considered to be one of the most important carcinogenic pathways in human cancer. Research have confirmed that the Wnt/β-catenin signaling pathway is an important driving factor for the occurrence and development of osteosarcoma, and abnormal activation of this pathway can promote the pathological processes of cell proliferation, invasion, migration, tumor angiogenesis and chemical resistance of osteosarcoma. However, inhibition of Wnt/β-catenin signaling pathway can effectively inhibit or reverse the above pathological processes. Therefore, manipulating the expression or function of the Wnt/β-catenin pathway may be a potential targeted pathway for the treatment of OS. In this review, we describe the characteristics of the Wnt/β-catenin signaling pathway and summarize the role and mechanism of this pathway in OS. This paper discusses the therapeutic significance of inhibiting or targeting Wnt/β-catenin pathway in OS and the shortcomings of current studies on this pathway in OS and the problems to be solved. This review helps us to understand the role of Wnt/β-catenin on OS, and provides a theoretical basis and new ideas for targeting Wnt/β-catenin pathway as a therapeutic target for OS.

References

Chou A, Gorlick R . Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006; 6(7):1075-85. DOI: 10.1586/14737140.6.7.1075. View

Wu Z, Zhou Z, Zhang W, Yu Y . MiR-21-5p inhibition attenuates Warburg effect and stemness maintenance in osteosarcoma cells via inactivation of Wnt/β-catenin signaling. Acta Biochim Pol. 2021; 68(4):725-732. DOI: 10.18388/abp.2020_5631. View

Self C, MacQuarrie K, Cost C . Osteosarcoma/Ewing Sarcoma. Pediatr Rev. 2022; 43(5):256-265. DOI: 10.1542/pir.2021-005065. View

Du Z, Li F, Wang L, Huang H, Xu S . Regulatory effects of microRNA‑184 on osteosarcoma via the Wnt/β‑catenin signaling pathway. Mol Med Rep. 2018; 18(2):1917-1924. PMC: 6072159. DOI: 10.3892/mmr.2018.9184. View

Liu Y, Wang W, Xu J, Li L, Dong Q, Shi Q . Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Oncol Rep. 2013; 30(4):1723-30. DOI: 10.3892/or.2013.2658. View

Ong P, Wang L, Dai X, Tseng S, Loo S, Sethi G . Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Front Pharmacol. 2016; 7:395. PMC: 5079084. DOI: 10.3389/fphar.2016.00395. View

He Z, Wang B, Hu C, Zhao J . An overview of hydrogel-based intra-articular drug delivery for the treatment of osteoarthritis. Colloids Surf B Biointerfaces. 2017; 154:33-39. DOI: 10.1016/j.colsurfb.2017.03.003. View

Sha L, Ma D, Chen C . Exosome-mediated Hic-5 regulates proliferation and apoptosis of osteosarcoma via Wnt/β-catenin signal pathway. Aging (Albany NY). 2020; 12(23):23598-23608. PMC: 7762460. DOI: 10.18632/aging.103546. View

Le P, Keysar S, Miller B, Eagles J, Chimed T, Reisinger J . Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions. Mol Carcinog. 2018; 58(3):398-410. PMC: 6460915. DOI: 10.1002/mc.22937. View

10.

Huo N, Ichikawa Y, Kamiyama M, Ishikawa T, Hamaguchi Y, Hasegawa S . MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Lett. 2002; 177(1):95-100. DOI: 10.1016/s0304-3835(01)00772-8. View

11.

Ma Y, Zhu B, Liu X, Yu H, Yong L, Liu X . Inhibition of oleandrin on the proliferation show and invasion of osteosarcoma cells in vitro by suppressing Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res. 2015; 34:115. PMC: 4596494. DOI: 10.1186/s13046-015-0232-8. View

12.

Zhang A, He S, Sun X, Ding L, Bao X, Wang N . Wnt5a promotes migration of human osteosarcoma cells by triggering a phosphatidylinositol-3 kinase/Akt signals. Cancer Cell Int. 2014; 14(1):15. PMC: 3976035. DOI: 10.1186/1475-2867-14-15. View

13.

Guo Z, Hu X, Xing Z, Xing R, Lv R, Cheng X . Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway. Mol Cell Biochem. 2015; 406(1-2):111-9. PMC: 4502300. DOI: 10.1007/s11010-015-2429-8. View

14.

Rout-Pitt N, Farrow N, Parsons D, Donnelley M . Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology. Respir Res. 2018; 19(1):136. PMC: 6052671. DOI: 10.1186/s12931-018-0834-8. View

15.

Kim D, Kim B, Shin H, Kwon H, Park E . The protective effect of hispidin against hydrogen peroxide-induced apoptosis in H9c2 cardiomyoblast cells through Akt/GSK-3β and ERK1/2 signaling pathway. Exp Cell Res. 2014; 327(2):264-75. DOI: 10.1016/j.yexcr.2014.07.037. View

16.

Scholten 2nd D, Timmer C, Peacock J, Pelle D, Williams B, Steensma M . Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells. PLoS One. 2014; 9(10):e111431. PMC: 4210185. DOI: 10.1371/journal.pone.0111431. View

17.

Fleischmann R, Bliddal H, Blanco F, Schnitzer T, Peterfy C, Chen S . A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis Rheumatol. 2019; 71(7):1056-1069. DOI: 10.1002/art.40840. View

18.

Dai J, He H, Lin D, Wang C, Zhu Y, Xu D . Up-regulation of E-cadherin by saRNA inhibits the migration and invasion of renal carcinoma cells. Int J Clin Exp Pathol. 2020; 11(12):5792-5800. PMC: 6963106. View

19.

Clevers H . Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-80. DOI: 10.1016/j.cell.2006.10.018. View

20.

Bond M, Fabunmi R, Baker A, Newby A . Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 1998; 435(1):29-34. DOI: 10.1016/s0014-5793(98)01034-5. View